Novel biomarkers for outcome after allogeneic hematopoietic stem cell transplantation
Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a well-established curative treatment for various malignant hematological diseases. However, its clinical success is substantially limited by major complications including graft-vs.-host disease (GVHD) and relapse of the underlying disease. Although these complications are known to lead to significant morbidity and mortality, standardized pathways for risk stratification of patients undergoing allo-HSCT are lacking. Recent advances in the development of diagnostic and prognostic tools have allowed the identification of biomarkers in order to predict outcome after allo-HSCT. This review will provide a summary of clinically relevant biomarkers that have been studied to predict the development of acute GVHD, the responsiveness of affected patients to immunosuppressive treatment and the risk of non-relapse mortality. Furthermore, biomarkers associated with increased risk of relapse and subsequent mortality will be discussed
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Frontiers in immunology. - 11 (2020) , 1854, ISSN: 1664-3224
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2020
- Urheber
- DOI
-
10.3389/fimmu.2020.01854
- URN
-
urn:nbn:de:bsz:25-freidok-1673930
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:49 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chen, Sophia
- Zeiser, Robert
- Universität
Entstanden
- 2020
Ähnliche Objekte (12)
Intestinal microbiota influence immune tolerance post allogeneic hematopoietic cell transplantation and intestinal GVHD
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation
Editorial on translational research in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effect after allogeneic hematopoietic cell transplantation
Monitoring of measurable residual disease using circulating DNA after allogeneic hematopoietic cell transplantation
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study
Advances in understanding the pathogenesis of graft‐versus‐host disease
Cellular and humoral SARS-CoV-2 vaccination responses in 192 adult recipients of allogeneic hematopoietic cell transplantation
The Hematopoietic niche in myeloproliferative neoplasms
Granulocyte macrophage colony-stimulating factor in allogenic hematopoietic stem cell transplantation: from graft-versus-host disease to the graft-versus-tumor effect
Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure
Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation
Intestinal microbiota influence immune tolerance post allogeneic hematopoietic cell transplantation and intestinal GVHD
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation
Editorial on translational research in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effect after allogeneic hematopoietic cell transplantation
Monitoring of measurable residual disease using circulating DNA after allogeneic hematopoietic cell transplantation
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study
Advances in understanding the pathogenesis of graft‐versus‐host disease
Cellular and humoral SARS-CoV-2 vaccination responses in 192 adult recipients of allogeneic hematopoietic cell transplantation
The Hematopoietic niche in myeloproliferative neoplasms
Granulocyte macrophage colony-stimulating factor in allogenic hematopoietic stem cell transplantation: from graft-versus-host disease to the graft-versus-tumor effect
Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure
Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation
Intestinal microbiota influence immune tolerance post allogeneic hematopoietic cell transplantation and intestinal GVHD
FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation
Editorial on translational research in graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) effect after allogeneic hematopoietic cell transplantation
Monitoring of measurable residual disease using circulating DNA after allogeneic hematopoietic cell transplantation
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study
Advances in understanding the pathogenesis of graft‐versus‐host disease
Cellular and humoral SARS-CoV-2 vaccination responses in 192 adult recipients of allogeneic hematopoietic cell transplantation
The Hematopoietic niche in myeloproliferative neoplasms
Granulocyte macrophage colony-stimulating factor in allogenic hematopoietic stem cell transplantation: from graft-versus-host disease to the graft-versus-tumor effect
Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure